Statins for all patients with type 2 diabetes: not so soon.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

1. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.BMJ (Clinical research ed.) · 2006
   Pooled it
2. Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study.Journal of clinical hypertension (Greenwich, Conn.) · 2010
   Trial
3. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus.Heart (British Cardiac Society) · 2007
   Trial
4. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.Experimental and clinical cardiology · 2007
   Article
5. Statins and CVD prevention in the diabetic population: implications of the CARDS trial.Current diabetes reports · 2005
   Review
6. The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Journal of negative results in biomedicine · 2005
   Review
7. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.Drugs · 2005
   Review
8. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.Vascular health and risk management · 2005
   Review

Corrections and comments

• Comment on
  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as